Bexson Biomedical
Bexson Biomedical is developing ketamine for pain management and mental health disorders, and applying a proprietary delivery system to several psychedelic and non-psychedelic compounds. In 2020, it partnered with Stevanato for the development of ketamine in a wearable subcutaneous injector.
Headquarters
Bexson Biomedical, Inc
PO Box 713
Santa Barbara
CA 93102
United States
Bexson Biomedical is a research-stage company developing BB106, a ketamine therapy for pain management and mental health disorders. In 2020, Bexson partnered with Stevanato Group on the development of ketamine in a wearable injector device. The company is also applying its own proprietary delivery system to several psychedelic and non-psychedelic compounds.
Bexson Biomedical was founded in 2017. It is privately owned.
